

Data Set Name: adm.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	DISCPTST	Char	1	\$X6675X.	\$1.	Pt Status at Discharge
2	PHSPREAS	Char	2	\$X6676X.	\$2.	Prim Reason for Re-Admit
3	REASGVHD	Char	1	\$X6677X.	\$1.	GVHD
4	REASRLPS	Char	1	\$X7600X.	\$1.	Relapse/Progression
5	REASGF	Char	1	\$X7601X.	\$1.	Graft Failure
6	REASINF	Char	1	\$X7602X.	\$1.	Infection
7	REASFVR	Char	1	\$X7640X.	\$1.	Fever
8	REASSZR	Char	1	\$X7641X.	\$1.	Seizure
9	REASGIBL	Char	1	\$X7642X.	\$1.	Bleeding
10	REASDRH	Char	1	\$X7643X.	\$1.	Diarrhea
11	REASNV	Char	1	\$X7644X.	\$1.	Nausea/Vomiting
12	REASORGF	Char	1	\$X8261X.	\$1.	Organ Failure
13	REASTRAM	Char	1	\$X8262X.	\$1.	Trauma
14	REASPSYC	Char	1	\$X8263X.	\$1.	Psychiatric
15	REASMALG	Char	1	\$X8264X.	\$1.	Secondary Malignancy
16	REASOTHR	Char	1	\$X8267X.	\$1.	Other
17	ADMCENTR	Char	1	\$X8268X.	\$1.	Re-Admission Center
18	rand_id	Char	10			Randomized subject ID
19	admitdays	Num	8			Days to Admission Since Enrollment
20	dischdays	Num	8			Days to Discharge Since Enrollment

Data Set Name: ae.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	ADVENT	Char	35	\$35.	\$35.	Event description
2	AVSTATUS	Char	1	\$X12046X.	\$1.	Activation status
3	AVWGHTKG	Num	8	7.1	7.1	Weight in kilograms
4	AVEXPECT	Char	1	\$X12047X.	\$1.	Expected
5	AVEVENT	Char	1	\$X12048X.	\$1.	Severity of event
6	AVRELAT	Char	1	\$X12049X.	\$1.	Relationship to study pro
7	AVETIOL	Char	1	\$X12054X.	\$1.	Alternative etiology
8	AVEFFECT	Char	1	\$X12055X.	\$1.	Effect on therapy/interven
9	AVOUTCOM	Char	1	\$X12056X.	\$1.	Outcome of the event
10	AVASSOCI	Char	1	\$X12057X.	\$1.	Event associated with
11	SEMEDHXS	Char	1	\$X12059X.	\$1.	Relevant past med hx
12	RCVSP	Char	1	\$X12061X.	\$1.	Receiving study products
13	SPNAME1	Char	20	\$20.	\$20.	Study product name 1
14	SP1DOSE	Char	12	\$12.	\$12.	Study product 1 dose
15	SP1ROUTE	Char	10	\$10.	\$10.	Study product 1 route
16	SP1SCHED	Char	12	\$12.	\$12.	Study product 1 schedule
17	SP1REASO	Char	25	\$25.	\$25.	Study product 1 reason
18	RCVCONMD	Char	1	\$X12062X.	\$1.	Receiving con meds
19	CONMED1	Char	30	\$30.	\$30.	Concomitant Medication 1
20	CM1DOSE	Char	20	\$20.	\$20.	Con med 1 dose/route/sche
21	CM1INDIC	Char	1	\$X12376X.	\$1.	Con med 1 indication
22	CONMED2	Char	30	\$30.	\$30.	Concomitant Medication 2
23	CM2DOSE	Char	20	\$20.	\$20.	Con med 2 dose/route/sche
24	CM2INDIC	Char	1	\$X12377X.	\$1.	Con med 2 indication
25	CONMED3	Char	30	\$30.	\$30.	Concomitant Medication 3
26	CM3DOSE	Char	20	\$20.	\$20.	Con med 3 dose/route/sche
27	CM3INDIC	Char	1	\$X12378X.	\$1.	Con med 3 indication
28	LABTSTPF	Char	1	\$X12064X.	\$1.	Lab tests performed
29	ADLTST1	Char	20	\$20.	\$20.	Laboratory test 1
30	ADL1RES	Char	10	\$10.	\$10.	Lab test 1 result
31	ADL1NORG	Char	15	\$15.	\$15.	Lab test 1 normal range
32	ADL1PRVL	Char	10	\$10.	\$10.	Lab test 1 previous value
33	DXSTPF	Char	1	\$X12065X.	\$1.	Diagnostic tests perform
34	ADDTS1	Char	20	\$20.	\$20.	Diagnostic test 1
35	AMDETER	Char	1	\$X12069X.	\$1.	SAE determined
36	AMEXPDSM	Char	1	\$X12075X.	\$1.	Expedite reporting DSMB

Num	Variable	Type	Len	Format	Informat	Label
37	AMWITHDR	Char	1	\$X12076X.	\$1.	Subject withdrawn
38	AMREVDNE	Char	1	\$X12077X.	\$1.	Review complete
39	AMMMEVDS	Char	35	\$35.	\$35.	MM event description
40	rand_id	Char	10			Randomized subject ID
41	advdays	Num	8			Days to Adverse Event Onset Since Enrollment
42	avawardays	Num	8			Days to Site Awareness of Adverse Event Since Enrollment
43	avresdays	Num	8			Days to Event Resolution Since Enrollment
44	seisubdays	Num	8			Days to Initial Form Submission Since Enrollment
45	seasubdays	Num	8			Days to Authorized Form Submission Since Enrollment
46	sp1stdays	Num	8			Days to Study Product 1 Start Since Enrollment
47	sp1spdays	Num	8			Days to Study Product 1 Stop Since Enrollment
48	cm1stdays	Num	8			Days to Concomitant Medication 1 Start Since Enrollment
49	cm1spdays	Num	8			Days to Concomitant Medication 1 Stop Since Enrollment
50	cm2stdays	Num	8			Days to Concomitant Medication 2 Start Since Enrollment
51	cm2spdays	Num	8			Days to Concomitant Medication 2 Stop Since Enrollment
52	cm3stdays	Num	8			Days to Concomitant Medication 3 Start Since Enrollment
53	cm3spdays	Num	8			Days to Concomitant Medication 3 Stop Since Enrollment
54	adl1cdays	Num	8			Days to Lab Test 1 Collection Since Enrollment
55	adl1pcdays	Num	8			Days to Lab Test 1 Previous Collection Since Enrollment
56	ad1dtdays	Num	8			Days to Diagnostic Test 1 Since Enrollment

Data Set Name: bsl.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	PREGNANT	Char	10	\$X9X.	\$10.	Pregnant or breastfeeding
2	CARDIAC	Char	10	\$X10X.	\$10.	Cardiac Insufficiency?
3	INFECT	Char	10	\$X11X.	\$10.	Uncontrolled Infection
4	PHASE1	Char	10	\$X12X.	\$10.	Concurrent Phase 1 study?
5	HIVPOS	Char	1	\$X13X.	\$1.	Is patient HIV positive
6	CBC	Char	5	\$X14X.	\$5.	CBC (Diff. and platelet)
7	PRCLEUBL	Num	8	4.	4.	Leukemic blast percent
8	SRCEBLST	Char	1	\$X15X.	\$1.	Source of leukemic blast
9	PRCPROMY	Num	8	4.	4.	Promyelocytes percent
10	SRCEPROM	Char	1	\$X217X.	\$1.	Source of promyelocytes
11	PERDLCO	Num	8	4.	4.	Percent DLCO
12	PERFEV1	Num	8	4.	4.	Percent FEV1
13	PERFEC	Num	8	4.	4.	Percent FVC
14	PFTYN	Char	1	\$X224X.	\$1.	PFTs performed
15	OXYSTRN	Num	8	4.	4.	O2 Saturation
16	CREATMRV	Num	8	5.1	5.1	Creatinine recent value
17	CREATLLN	Num	8	5.1	5.1	LLN for creatinine
18	CREATULN	Num	8	5.1	5.1	ULN for creatinine
19	ALTMRV	Num	8	4.	4.	ALT recent value
20	ALTULN	Num	8	4.	4.	ULN for ALT
21	ASTMRV	Num	8	4.	4.	AST recent value
22	ASTULN	Num	8	4.	4.	ULN for AST
23	BILIMRV	Num	8	5.1	5.1	Bilirubin recent value
24	BILIULN	Num	8	6.1	6.1	ULN for bilirubin
25	rand_id	Char	10			Randomized subject ID
26	daysdlco	Num	8			Days to DLCO Sample Obtained Since Enrollment
27	daysfev1	Num	8			Days to FEV1 Sample Obtained Since Enrollment
28	daysfec	Num	8			Days to FVC Sample Obtained Since Enrollment
29	daysoxy	Num	8			Days to Oxygen Saturation Sample Obtained Since Enrollment
30	creatdays	Num	8			Days to Creatinine Sample Obtained Since Enrollment
31	altdays	Num	8			Days to ALT Sample Obtained Since Enrollment
32	astdays	Num	8			Days to AST Sample Obtained Since Enrollment
33	bilidays	Num	8			Days to Bilirubin Sample Obtained Since Enrollment

Data Set Name: cgv.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	VISNO	Char	4	\$4.	\$4.	VISNO
2	GRDAGVHD	Char	1	\$X6807X.	\$1.	Max Grade of aGVHD
3	AGVDVLP	Char	1	\$X6808X.	\$1.	aGVHD Develop This Assess
4	DGNSAGVH	Char	1	\$X6809X.	\$1.	Method To Diagnose aGVHD
5	PROPHIMM	Char	1	\$X6976X.	\$1.	Immuno for Prophylaxis
6	PROPHCY	Char	1	\$X6977X.	\$1.	Cyclosporine Prophylaxis
7	PROPHTAC	Char	1	\$X6978X.	\$1.	Tacrolimus Prophylaxis
8	PROPHSIR	Char	1	\$X6979X.	\$1.	Sirolimus Prophylaxis
9	PROPHMMF	Char	1	\$X6980X.	\$1.	MMF Prophylaxis
10	PROPHPRD	Char	1	\$X6981X.	\$1.	Prednisone Prophylaxis
11	PROPHOTH	Char	1	\$X6982X.	\$1.	Other Prophylaxis
12	PRPHOTSP	Char	50	\$50.	\$50.	Specify Other Prophylaxis
13	SEVCGVHD	Char	1	\$X6983X.	\$1.	Max Severity of cGVHD
14	GRDCGVHD	Char	1	\$X6984X.	\$1.	Max Grade of cGVHD
15	CGVDVLP	Char	1	\$X7071X.	\$1.	cGVHD Develop This Assess
16	DGNSCGVH	Char	1	\$X7072X.	\$1.	Method To Diagnose cGVHD
17	CGVKRNLN	Char	2	\$X7073X.	\$2.	Karnofsky/Lansky Score
18	PLTLTCNT	Num	8	7.1	7.1	Platelet Count
19	ALKPHOSP	Num	8	5.	5.	Alkaline Phosphatase
20	CGVWEIGH	Num	8	7.1	7.1	CGV Weight
21	BILIRUBN	Num	8	6.1	6.1	Total Bilirubin
22	BSA	Num	8	4.	4.	Body Surface Area
23	CGVRASH	Char	1	\$X7074X.	\$1.	GVHD Rash
24	RASHLICH	Char	1	\$X7075X.	\$1.	Lichenoid Rash
25	RASHMACU	Char	1	\$X7076X.	\$1.	Maculopapular Rash
26	RASHSCLR	Char	1	\$X7077X.	\$1.	Sclerodermatous Rash
27	DRYEYES	Char	1	\$X7078X.	\$1.	Xerophthalmia
28	MUCOFXN	Char	1	\$X7402X.	\$1.	Mucositis (functional)
29	CGVDYSPN	Char	1	\$X7403X.	\$1.	Dyspnea
30	PULMFIBR	Char	1	\$X7404X.	\$1.	Pulmonary Fibrosis
31	BRNCOBLT	Char	1	\$X7405X.	\$1.	Bronchiolitis Obliterans
32	CGVFEV1	Char	1	\$X7406X.	\$1.	FEV1
33	O2SAT	Char	1	\$X7407X.	\$1.	O2 Saturation
34	ESOPHAGS	Char	1	\$X7408X.	\$1.	Esophagus
35	NAUSVOMT	Char	1	\$X7409X.	\$1.	Nausea and Vomiting
36	CGVDIARH	Char	1	\$X7410X.	\$1.	Diarrhea

Num	Variable	Type	Len	Format	Informat	Label
37	DIARHMSR	Char	1	\$X7411X.	\$1.	Diarrhea Measurement
38	DIARHEA1	Char	1	\$X7412X.	\$1.	Diarrhea - Stools
39	DIARHEA2	Char	1	\$X7413X.	\$1.	Diarrhea - Volume
40	MALABSRP	Char	1	\$X7422X.	\$1.	Malabsorption
41	LIVERBIL	Char	1	\$X7423X.	\$1.	Liver Bilirubin
42	VAGNITIS	Char	1	\$X7424X.	\$1.	Vaginitis
43	CONTRCTR	Char	1	\$X7425X.	\$1.	Contractures
44	MYOSITIS	Char	1	\$X7426X.	\$1.	Myositis
45	EOSINPHL	Char	1	\$X7427X.	\$1.	Eosinophilia
46	SEROSITS	Char	1	\$X7428X.	\$1.	Serositis
47	FASCITIS	Char	1	\$X7429X.	\$1.	Fascitis
48	ORGNOTHR	Char	1	\$X7430X.	\$1.	Other Organ Involve
49	ORGSPEC	Char	50	\$50.	\$50.	Specify Other Organ
50	BIOPSY	Char	1	\$X7431X.	\$1.	Biopsy for GVHD
51	BIOTYP1	Char	1	\$X7926X.	\$1.	Biopsy Type 1
52	TYP1OSPE	Char	20	\$20.	\$20.	Biopsy1 Other Specify
53	BIORSLT1	Char	1	\$X7927X.	\$1.	Biopsy Result 1
54	BIOTYP2	Char	1	\$X7928X.	\$1.	Biopsy Type 2
55	TYP2OSPE	Char	20	\$20.	\$20.	Biopsy2 Other Specify
56	BIORSLT2	Char	1	\$X7929X.	\$1.	Biopsy Result 2
57	THRPYUSD	Char	1	\$X7432X.	\$1.	Was Therapy Used
58	THRPYATG	Char	1	\$X7433X.	\$1.	ALS, ALG, ATS, ATG
59	THRPYAZA	Char	1	\$X7434X.	\$1.	Azathioprine
60	THRPYCYC	Char	1	\$X7435X.	\$1.	Cyclosporine
61	THRPYSCO	Char	1	\$X7436X.	\$1.	Systemic Corticosteroids
62	THRPYTCO	Char	1	\$X7455X.	\$1.	Topical Corticosteroids
63	THRPYTHA	Char	1	\$X7456X.	\$1.	Thalidomide
64	THRPYTAC	Char	1	\$X7457X.	\$1.	Tacrolimus-FK506,Prograf
65	THRPYMMF	Char	1	\$X7458X.	\$1.	Mycophenolate Mofetil
66	THRPYPUV	Char	1	\$X7459X.	\$1.	PUVA
67	THRPYECP	Char	1	\$X7460X.	\$1.	ECP
68	THRPYSIR	Char	1	\$X7461X.	\$1.	Sirolimus
69	THRPYETR	Char	1	\$X7462X.	\$1.	Etretinate
70	THRPYLAM	Char	1	\$X7463X.	\$1.	Lamprene
71	THRPYETA	Char	1	\$X7464X.	\$1.	Etanercept
72	THRPYZEN	Char	1	\$X7506X.	\$1.	Zenapax
73	THRPYCPH	Char	1	\$X7507X.	\$1.	Chloroquine Phosphate
74	THRPYMAB	Char	1	\$X7508X.	\$1.	In Vivo MAB
75	MABAGNT	Char	50	\$50.	\$50.	Specify MAB Agent

Num	Variable	Type	Len	Format	Informat	Label
76	THRPYIMM	Char	1	\$X7509X.	\$1.	In Vivio Immunotoxin
77	IMMAGNT	Char	50	\$50.	\$50.	Specify Immuno. Agent
78	THRPYOTH	Char	1	\$X7510X.	\$1.	Other Therapy
79	OTHAGNT	Char	50	\$50.	\$50.	Specify Other Agent
80	ONGTRT	Char	1	\$X7527X.	\$1.	Treatment Discontinued
81	THRPYRSP	Char	1	\$X7528X.	\$1.	Response to GVHD Therapy
82	GVHDSYMP	Char	1	\$X7529X.	\$1.	GVHD Symptoms Present
83	CURKRNLN	Char	2	\$X7530X.	\$2.	Current Karnofsky/Lansky
84	CURPLTCT	Num	8	7.1	7.1	Current Platelet Count
85	CURWGHT	Num	8	7.1	7.1	Current Weight
86	rand_id	Char	10			Randomized subject ID
87	daysprvast	Num	8			Days to Start of Follow-up Assessment Since Enrollment
88	daysassess	Num	8			Days to End of Follow-up Assessment Since Enrollment
89	daysdgnagv	Num	8			Days to aGVHD Diagnosis Since Enrollment
90	prphdiscdays	Num	8			Days to GVHD Prophylaxis Discontinuation Since Enrollment
91	daysdgnegv	Num	8			Days to cGVHD Diagnosis Since Enrollment
92	biodays1	Num	8			Days to Biopsy 1 Since Enrollment
93	biodays2	Num	8			Days to Biopsy 2 Since Enrollment
94	trtstopdays	Num	8			Days to End of GVHD Therapy Treatment Since Enrollment

Data Set Name: ctn0201_lfu.sas7bdat

Num	Variable	Type	Len	Label
1	rand_id	Char	10	Randomized subject ID
2	ose_srvcens_5y	Num	8	Overall survival indicator at year 5 (1 = Dead, 0 = Alive)
3	ose_srvtm_5y	Num	8	Time in days from enrollment to last follow up/death by year 5

Data Set Name: dem.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	GENDER	Char	1	\$1.	\$1.	GENDER
2	ETHNIC	Char	3	\$3.	\$3.	ETHNIC
3	RACE	Char	2	\$2.	\$2.	RACE
4	RACE2	Char	2	\$2.	\$2.	RACE2
5	rand_id	Char	10			Randomized subject ID

Data Set Name: dnr.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	DAGE	Num	8	3.	3.	Donor age
2	DGENDER	Char	1	\$X2641X.	\$1.	Donor gender
3	DETHNIC	Char	1	\$X2647X.	\$1.	Donor ethnicity
4	DRACE	Char	2	\$X2648X.	\$2.	Donor race
5	DVENACCE	Char	1	\$X2649X.	\$1.	Donor venous access
6	DCRITERI	Char	1	\$X3291X.	\$1.	Donor meets incl criteria
7	DSAEANES	Char	1	\$X3292X.	\$1.	Donor reaction to aneste
8	DPREGN	Char	1	\$X3293X.	\$1.	Donor pregnant
9	DALLERGY	Char	1	\$X3294X.	\$1.	Donor allergy
10	DAUTOIHX	Char	1	\$X3376X.	\$1.	Donor autoimmune history
11	DDVTHX	Char	1	\$X3377X.	\$1.	Donor DVT history
12	DIRIEHX	Char	1	\$X3378X.	\$1.	Donor iritis episc hx
13	DLITHIUM	Char	1	\$X3379X.	\$1.	Donor on lithium
14	DPOSHST	Char	1	\$X3380X.	\$1.	Donor positive Hgb Solu
15	DEXPERIM	Char	1	\$X3381X.	\$1.	Donor on experimental tx
16	DCMVST	Char	1	\$X3382X.	\$1.	Donor DMV status
17	DPLATELE	Num	8	7.	7.	Platelets
18	DQOLAGRE	Char	1	\$X3383X.	\$1.	Donor agrees to QOL
19	DINELIG	Char	1	\$X3384X.	\$1.	Donor became ineligible
20	DINELSP	Char	75	\$75.	\$75.	Ineligible specify reason
21	dcnstdays	Num	8			Days to Signing of Donor Informed Consent Form Since Enrollment
22	rand_donor_id	Char	9			Randomized donor ID
23	rand_id	Char	10			Randomized subject ID

Data Set Name: *dth.sas7bdat*

Num	Variable	Type	Len	Format	Informat	Label
1	AUTPERF	Char	1	\$X6864X.	\$1.	Autopsy performed
2	CZDTHPRM	Char	4	\$X7040X.	\$4.	Primary Cause of Death
3	SCNDCZ1	Char	4	\$X7041X.	\$4.	Secondary cause death
4	rand_id	Char	10			Randomized subject ID
5	dthdays	Num	8			Days to Death Since Enrollment

Data Set Name: enr.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	GVHDREG	Char	1	\$X569X.	\$1.	GVHD prophylaxis regimen
2	GVHDOTHR	Char	30	\$30.	\$30.	GVHD other regimen
3	CONDREGI	Char	1	\$X570X.	\$1.	Conditioning regimen
4	CAMPATH	Char	1	\$X571X.	\$1.	Alemtuzumab (Campath-1H)
5	PPRIMDX	Char	1	\$X572X.	\$1.	Participant primary dx
6	AMLDSSTG	Char	1	\$X858X.	\$1.	AML disease stage
7	ALLDSSTG	Char	1	\$X859X.	\$1.	ALL disease stage
8	CMLDSSTG	Char	1	\$X860X.	\$1.	CML disease stage
9	MDSDSSTG	Char	1	\$X861X.	\$1.	MDS disease stage
10	TRPYAML	Char	1	\$X862X.	\$1.	Thrpy Related AML or MDS
11	PMALTIME	Char	1	\$X863X.	\$1.	Time Prior Malign Remissn
12	PPRALLOG	Char	1	\$X865X.	\$1.	Prior Allo or Auto Txp
13	PRTRNSPL	Char	1	\$X866X.	\$1.	Type of Prior Txp
14	PMALAUTO	Char	1	\$X867X.	\$1.	Auto Txp for Prior Malign
15	AUTOPRDT	Char	1	\$X868X.	\$1.	Auto Txp Date Prior Enrol
16	CNSTRSCH	Char	1	\$X869X.	\$1.	Consent for Research
17	STRATA	Char	3	\$3.	\$3.	Stratum
18	COMMENTR0	Char	38	\$38.	\$2000.	Comments ENR Segment 0
19	HLAMATCH	Char	30	\$30.	\$30.	ProtSeg HLA match type
20	RHLAAMET	Char	1	\$1.	\$1.	Recip HLA-A Typing Method
21	RHLAANUM	Char	1	\$1.	\$1.	Recip HLA-A Number Allele
22	RHLAA11X	Char	5	\$5.	\$5.	Recip HLA-A 1st Allele 1
23	RHLAA12X	Char	5	\$5.	\$5.	Recip HLA-A 1st Allele 2
24	RHLAA13X	Char	5	\$5.	\$5.	Recip HLA-A 1st Allele 3
25	RHLAA14X	Char	5	\$5.	\$5.	Recip HLA-A 1st Allele 4
26	RHLAA15X	Char	5	\$5.	\$5.	Recip HLA-A 1st Allele 5
27	RHLAA16X	Char	5	\$5.	\$5.	Recip HLA-A 1st Allele 6
28	RHLAA17X	Char	5	\$5.	\$5.	Recip HLA-A 1st Allele 7
29	RHLAA18X	Char	5	\$5.	\$5.	Recip HLA-A 1st Allele 8
30	RHLAA21X	Char	5	\$5.	\$5.	Recip HLA-A 2nd Allele 1
31	RHLAA22X	Char	5	\$5.	\$5.	Recip HLA-A 2nd Allele 2
32	RHLAA23X	Char	5	\$5.	\$5.	Recip HLA-A 2nd Allele 3
33	RHLAA24X	Char	5	\$5.	\$5.	Recip HLA-A 2nd Allele 4
34	RHLAA25X	Char	5	\$5.	\$5.	Recip HLA-A 2nd Allele 5
35	RHLAA26X	Char	5	\$5.	\$5.	Recip HLA-A 2nd Allele 6
36	RHLAA27X	Char	5	\$5.	\$5.	Recip HLA-A 2nd Allele 7

Num	Variable	Type	Len	Format	Informat	Label
37	RHLAA28X	Char	5	\$5.	\$5.	Recip HLA-A 2nd Allele 8
38	RHLABMET	Char	1	\$1.	\$1.	Recip HLA-B Typing Method
39	RHLABNUM	Char	1	\$1.	\$1.	Recip HLA-B Number Allele
40	RHLAB11X	Char	5	\$5.	\$5.	Recip HLA-B 1st Allele 1
41	RHLAB12X	Char	5	\$5.	\$5.	Recip HLA-B 1st Allele 2
42	RHLAB13X	Char	5	\$5.	\$5.	Recip HLA-B 1st Allele 3
43	RHLAB14X	Char	5	\$5.	\$5.	Recip HLA-B 1st Allele 4
44	RHLAB15X	Char	5	\$5.	\$5.	Recip HLA-B 1st Allele 5
45	RHLAB16X	Char	5	\$5.	\$5.	Recip HLA-B 1st Allele 6
46	RHLAB17X	Char	5	\$5.	\$5.	Recip HLA-B 1st Allele 7
47	RHLAB18X	Char	5	\$5.	\$5.	Recip HLA-B 1st Allele 8
48	RHLAB21X	Char	5	\$5.	\$5.	Recip HLA-B 2nd Allele 1
49	RHLAB22X	Char	5	\$5.	\$5.	Recip HLA-B 2nd Allele 2
50	RHLAB23X	Char	5	\$5.	\$5.	Recip HLA-B 2nd Allele 3
51	RHLAB24X	Char	5	\$5.	\$5.	Recip HLA-B 2nd Allele 4
52	RHLAB25X	Char	5	\$5.	\$5.	Recip HLA-B 2nd Allele 5
53	RHLAB26X	Char	5	\$5.	\$5.	Recip HLA-B 2nd Allele 6
54	RHLAB27X	Char	5	\$5.	\$5.	Recip HLA-B 2nd Allele 7
55	RHLAB28X	Char	5	\$5.	\$5.	Recip HLA-B 2nd Allele 8
56	RHLACMET	Char	1	\$1.	\$1.	Recip HLA-C Typing Method
57	RHLACNUM	Char	1	\$1.	\$1.	Recip HLA-C Number Allele
58	RHLAC11X	Char	5	\$5.	\$5.	Recip HLA-C 1st Allele 1
59	RHLAC12X	Char	5	\$5.	\$5.	Recip HLA-C 1st Allele 2
60	RHLAC13X	Char	5	\$5.	\$5.	Recip HLA-C 1st Allele 3
61	RHLAC14X	Char	5	\$5.	\$5.	Recip HLA-C 1st Allele 4
62	RHLAC15X	Char	5	\$5.	\$5.	Recip HLA-C 1st Allele 5
63	RHLAC16X	Char	5	\$5.	\$5.	Recip HLA-C 1st Allele 6
64	RHLAC17X	Char	5	\$5.	\$5.	Recip HLA-C 1st Allele 7
65	RHLAC18X	Char	5	\$5.	\$5.	Recip HLA-C 1st Allele 8
66	RHLAC21X	Char	5	\$5.	\$5.	Recip HLA-C 2nd Allele 1
67	RHLAC22X	Char	5	\$5.	\$5.	Recip HLA-C 2nd Allele 2
68	RHLAC23X	Char	5	\$5.	\$5.	Recip HLA-C 2nd Allele 3
69	RHLAC24X	Char	5	\$5.	\$5.	Recip HLA-C 2nd Allele 4
70	RHLADMET	Char	1	\$1.	\$1.	Recip HLA-D Typing Method
71	RHLADNUM	Char	1	\$1.	\$1.	Recip HLA-D Number Allele
72	RHLAD11X	Char	5	\$5.	\$5.	Recip HLA-D 1st Allele 1
73	RHLAD12X	Char	5	\$5.	\$5.	Recip HLA-D 1st Allele 2
74	RHLAD21X	Char	5	\$5.	\$5.	Recip HLA-D 2nd Allele 1
75	RHLAD22X	Char	5	\$5.	\$5.	Recip HLA-D 2nd Allele 2

Num	Variable	Type	Len	Format	Informat	Label
76	RHLAD23X	Char	5	\$5.	\$5.	Recip HLA-D 2nd Allele 3
77	DHLAAMET	Char	1	\$1.	\$1.	Donor HLA-A Typing Method
78	DHLAANUM	Char	1	\$1.	\$1.	Donor HLA-A Number Allele
79	DHLAA11X	Char	5	\$5.	\$5.	Donor HLA-A 1st Allele 1
80	DHLAA12X	Char	5	\$5.	\$5.	Donor HLA-A 1st Allele 2
81	DHLAA13X	Char	5	\$5.	\$5.	Donor HLA-A 1st Allele 3
82	DHLAA14X	Char	5	\$5.	\$5.	Donor HLA-A 1st Allele 4
83	DHLAA15X	Char	5	\$5.	\$5.	Donor HLA-A 1st Allele 5
84	DHLAA16X	Char	5	\$5.	\$5.	Donor HLA-A 1st Allele 6
85	DHLAA17X	Char	5	\$5.	\$5.	Donor HLA-A 1st Allele 7
86	DHLAA18X	Char	5	\$5.	\$5.	Donor HLA-A 1st Allele 8
87	DHLAA21X	Char	5	\$5.	\$5.	Donor HLA-A 2nd Allele 1
88	DHLAA22X	Char	5	\$5.	\$5.	Donor HLA-A 2nd Allele 2
89	DHLAA23X	Char	5	\$5.	\$5.	Donor HLA-A 2nd Allele 3
90	DHLAA24X	Char	5	\$5.	\$5.	Donor HLA-A 2nd Allele 4
91	DHLAA25X	Char	5	\$5.	\$5.	Donor HLA-A 2nd Allele 5
92	DHLAA26X	Char	5	\$5.	\$5.	Donor HLA-A 2nd Allele 6
93	DHLAA27X	Char	5	\$5.	\$5.	Donor HLA-A 2nd Allele 7
94	DHLAA28X	Char	5	\$5.	\$5.	Donor HLA-A 2nd Allele 8
95	DHLABMET	Char	1	\$1.	\$1.	Donor HLA-B Typing Method
96	DHLABNUM	Char	1	\$1.	\$1.	Donor HLA-B Number Allele
97	DHLAB11X	Char	5	\$5.	\$5.	Donor HLA-B 1st Allele 1
98	DHLAB12X	Char	5	\$5.	\$5.	Donor HLA-B 1st Allele 2
99	DHLAB13X	Char	5	\$5.	\$5.	Donor HLA-B 1st Allele 3
100	DHLAB14X	Char	5	\$5.	\$5.	Donor HLA-B 1st Allele 4
101	DHLAB15X	Char	5	\$5.	\$5.	Donor HLA-B 1st Allele 5
102	DHLAB16X	Char	5	\$5.	\$5.	Donor HLA-B 1st Allele 6
103	DHLAB17X	Char	5	\$5.	\$5.	Donor HLA-B 1st Allele 7
104	DHLAB18X	Char	5	\$5.	\$5.	Donor HLA-B 1st Allele 8
105	DHLAB21X	Char	5	\$5.	\$5.	Donor HLA-B 2nd Allele 1
106	DHLAB22X	Char	5	\$5.	\$5.	Donor HLA-B 2nd Allele 2
107	DHLAB23X	Char	5	\$5.	\$5.	Donor HLA-B 2nd Allele 3
108	DHLAB24X	Char	5	\$5.	\$5.	Donor HLA-B 2nd Allele 4
109	DHLAB25X	Char	5	\$5.	\$5.	Donor HLA-B 2nd Allele 5
110	DHLAB26X	Char	5	\$5.	\$5.	Donor HLA-B 2nd Allele 6
111	DHLAB27X	Char	5	\$5.	\$5.	Donor HLA-B 2nd Allele 7
112	DHLAB28X	Char	5	\$5.	\$5.	Donor HLA-B 2nd Allele 8
113	DHLACMET	Char	1	\$1.	\$1.	Donor HLA-C Typing Method
114	DHLACNUM	Char	1	\$1.	\$1.	Donor HLA-C Number Allele

Num	Variable	Type	Len	Format	Informat	Label
115	DHLAC11X	Char	5	\$5.	\$5.	Donor HLA-C 1st Allele 1
116	DHLAC12X	Char	5	\$5.	\$5.	Donor HLA-C 1st Allele 2
117	DHLAC13X	Char	5	\$5.	\$5.	Donor HLA-C 1st Allele 3
118	DHLAC14X	Char	5	\$5.	\$5.	Donor HLA-C 1st Allele 4
119	DHLAC15X	Char	5	\$5.	\$5.	Donor HLA-C 1st Allele 5
120	DHLAC16X	Char	5	\$5.	\$5.	Donor HLA-C 1st Allele 6
121	DHLAC17X	Char	5	\$5.	\$5.	Donor HLA-C 1st Allele 7
122	DHLAC18X	Char	5	\$5.	\$5.	Donor HLA-C 1st Allele 8
123	DHLAC21X	Char	5	\$5.	\$5.	Donor HLA-C 2nd Allele 1
124	DHLAC22X	Char	5	\$5.	\$5.	Donor HLA-C 2nd Allele 2
125	DHLAC23X	Char	5	\$5.	\$5.	Donor HLA-C 2nd Allele 3
126	DHLAC24X	Char	5	\$5.	\$5.	Donor HLA-C 2nd Allele 4
127	DHLADMET	Char	1	\$1.	\$1.	Donor HLA-D Typing Method
128	DHLADNUM	Char	1	\$1.	\$1.	Donor HLA-D Number Allele
129	DHLAD11X	Char	5	\$5.	\$5.	Donor HLA-D 1st Allele 1
130	DHLAD12X	Char	5	\$5.	\$5.	Donor HLA-D 1st Allele 2
131	DHLAD21X	Char	5	\$5.	\$5.	Donor HLA-D 2nd Allele 1
132	DHLAD22X	Char	5	\$5.	\$5.	Donor HLA-D 2nd Allele 2
133	DHLAD23X	Char	5	\$5.	\$5.	Donor HLA-D 2nd Allele 3
134	HLASCREQ	Char	3	\$3.	\$3.	ProtSeg HLA score requird
135	SCORE_A	Char	3	\$3.	\$3.	HLA-A Match Score
136	SCORE_B	Char	3	\$3.	\$3.	HLA-B Match Score
137	SCORE_C	Char	3	\$3.	\$3.	HLA-C Match Score
138	SCORE_D	Char	3	\$3.	\$3.	HLA-DRB1 Match Score
139	HLASCORE	Char	3	\$3.	\$3.	Calc Hla Match Score
140	HLAAGREE	Char	1	\$1.	\$1.	Agree with BMT Hla Score
141	SITESCR	Char	3	\$3.	\$3.	Site Hla score
142	age	Num	8			Age at Enrollment(yrs)
143	rand_donor_id	Char	9			Randomized donor ID
144	rand_id	Char	10			Randomized subject ID
145	consntdays0	Num	8			Days to Signing of Informed Consent Form Since Enrollment

Data Set Name: fus.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	VISNO	Char	4	\$4.	\$4.	VISNO
2	DIED	Char	1	\$X329X.	\$1.	Patient Died
3	RELAPSE	Char	1	\$X330X.	\$1.	Relapsed
4	RELAPSTX	Char	1	\$X331X.	\$1.	Treated Relapse
5	TREATYPE	Char	1	\$X332X.	\$1.	Type of Treatment
6	FUS1SPEC	Char	50	\$50.	\$50.	Specify Other Treatment
7	SECGRFAL	Char	1	\$X361X.	\$1.	Secondary Graft Failure
8	NEWINFX	Char	1	\$X366X.	\$1.	Clinically Signif Inf
9	HOSPITAL	Char	1	\$X369X.	\$1.	Hospitalized
10	TRANSTWO	Char	1	\$X370X.	\$1.	Second Transplant
11	rand_id	Char	10			Randomized subject ID
12	lastctdays	Num	8			Days to Last Contact Since Enrollment
13	deathdays	Num	8			Days to Death Since Enrollment
14	relapsdays	Num	8			Days to Relapse Since Enrollment
15	treatdays	Num	8			Days to Relapse Treatment Since Enrollment
16	scgrfldays	Num	8			Days to Secondary Graft Failure Since Enrollment
17	infdays	Num	8			Days to New Clinically Significant Infection Since Enrollment
18	hosptldays	Num	8			Days to Hospitalization Since Enrollment
19	daystransp	Num	8			Days to Non-protocol Transplant Since Enrollment

Data Set Name: gvh.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	VISNO	Char	4	\$4.	\$4.	VISNO
2	IMMUNORC	Char	1	\$X7731X.	\$1.	Immunosuppressant Recvd
3	TROUGHVLV	Num	8	8.1	8.1	Most Recent Immun Level
4	GVHSKINA	Char	1	\$X7889X.	\$1.	Skin Abnormalities
5	SETGVHD	Char	1	\$X8255X.	\$1.	Skin Etiology GVHD
6	SETDRGRX	Char	1	\$X8256X.	\$1.	Skin Etiology Drug Reacti
7	SETCRTOX	Char	1	\$X8257X.	\$1.	Skin Etiology Cnd Reg Tox
8	SETINFCT	Char	1	\$X8258X.	\$1.	Skin Etiology Infection
9	SETOTHER	Char	1	\$X8259X.	\$1.	Skin Etiology Other
10	GVHSKNSP	Char	50	\$50.	\$50.	Skin Etiology Specify
11	GVHSKINB	Char	1	\$X7890X.	\$1.	Skin Biopsy Results
12	GVHUPGIA	Char	1	\$X7891X.	\$1.	Upper GI Abnormalities
13	UGIETGVH	Char	1	\$X8249X.	\$1.	UGI Etiology GVHD
14	UGIETDRG	Char	1	\$X8250X.	\$1.	UGI Etiology Drug Rxn
15	UGIETCON	Char	1	\$X8251X.	\$1.	UGI Etiology Cond Reg Tox
16	UGIETTPN	Char	1	\$X8252X.	\$1.	UGI Etiology TPN
17	UGIETINF	Char	1	\$X8253X.	\$1.	UGI Etiology Infection
18	UGIETOTH	Char	1	\$X8254X.	\$1.	UGI Etiology Other
19	UGIETSPC	Char	50	\$50.	\$50.	UGI Etiology Specify
20	UGIBIORS	Char	1	\$X7892X.	\$1.	UGI Biopsy Results
21	GVHINTA	Char	1	\$X7893X.	\$1.	Lower GI Abnormalities
22	LGIETGVH	Char	1	\$X8260X.	\$1.	LGI Etiology GVHD
23	LGIETDRG	Char	1	\$X8557X.	\$1.	LGI Etiology Drug Rxn
24	LGIETCON	Char	1	\$X8558X.	\$1.	LGI Etiology Cond Reg Tox
25	LGIETTPN	Char	1	\$X8559X.	\$1.	LGI Etiology TPN
26	LGIETINF	Char	1	\$X8560X.	\$1.	LGI Etiology Infection
27	LGIETOTH	Char	1	\$X8571X.	\$1.	LGI Etiology Other
28	LGIETSPC	Char	50	\$50.	\$50.	LGI Etiology Specify
29	LGIBIORS	Char	1	\$X7894X.	\$1.	LGI Biopsy Results
30	GVHLIVRA	Char	1	\$X7895X.	\$1.	Liver Abnormalities
31	LIVETGVH	Char	1	\$X8572X.	\$1.	Liver Etiology GVHD
32	LIVETDRG	Char	1	\$X8573X.	\$1.	Liver Etiology Drug Rxn
33	LIVETCND	Char	1	\$X8574X.	\$1.	Liver Etiology Cnd Reg Tx
34	LIVETTPN	Char	1	\$X8575X.	\$1.	Liver Etiology TPN
35	LIVETINF	Char	1	\$X8576X.	\$1.	Liver Etiology Infection
36	LIVETVOD	Char	1	\$X8577X.	\$1.	Liver Etiology VOD

Num	Variable	Type	Len	Format	Informat	Label
37	LIVETOTH	Char	1	\$X8578X.	\$1.	Liver Etiology Other
38	GVHLIVRS	Char	50	\$50.	\$50.	Liver Etiology Specify
39	GVHLIVRB	Char	1	\$X7901X.	\$1.	Liver Biopsy Results
40	GVHTHERP	Char	1	\$X7902X.	\$1.	GVHD Treatment Modified?
41	GVHAGENT	Char	1	\$X7903X.	\$1.	Agent Type
42	GVHAGNSP	Char	50	\$50.	\$50.	Specify Agent
43	GVHTRMOD	Char	1	\$X7904X.	\$1.	Modification of Treatment
44	rand_id	Char	10			Randomized subject ID
45	stagedays	Num	8			Days to GVHD Staging Since Enrollment
46	gvasstdays	Num	8			Days to Start of GVHD Assessment Period Since Enrollment
47	gvasendays	Num	8			Days to End of GVHD Assessment Period Since Enrollment
48	troughdays	Num	8			Days to Blood Sample Obtained Since Enrollment

Data Set Name: hem.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	VISNO	Char	4	\$4.	\$4.	VISNO
2	ENGRFT1	Char	1	\$X5627X.	\$1.	Engraftment
3	ANCDAY1	Num	8	6.	6.	ANC 1
4	ANCDAY2	Num	8	6.	6.	ANC 2
5	ANCDAY3	Num	8	6.	6.	ANC 3
6	MRWDONE	Char	1	\$X5640X.	\$1.	Marrow Done
7	MTHOD1	Char	1	\$X5641X.	\$1.	Primary Method 1
8	MRWSPEC	Char	25	\$25.	\$25.	Other - Marrow
9	MRWCLTYP	Char	1	\$X5642X.	\$1.	Marrow Cell Type
10	MRWASSAY	Char	1	\$X5643X.	\$1.	Assay Results 1
11	PCNTDNR1	Num	8	3.	3.	Percent Donor
12	BLDDONE	Char	1	\$X5647X.	\$1.	Blood Done
13	MTHOD2	Char	1	\$X5648X.	\$1.	Primary Method 2
14	BLDSPEC	Char	25	\$25.	\$25.	Other - Blood
15	BLDCLTYP	Char	1	\$X5649X.	\$1.	Blood Cell Type
16	BLDASSAY	Char	1	\$X5650X.	\$1.	Assay Results 2
17	PCNTDNR2	Num	8	3.	3.	Percent Donor
18	TCLDONE	Char	1	\$X5652X.	\$1.	T Cell Done
19	TCLSMPL	Char	1	\$X5653X.	\$1.	T Cell Sample Type
20	MTHOD3	Char	1	\$X5654X.	\$1.	Primary Method 3
21	TCLSPEC	Char	25	\$25.	\$25.	Other - T Cell
22	TCLASSAY	Char	1	\$X5655X.	\$1.	T Cell Assay Results
23	PCNTDNR3	Num	8	3.	3.	Percent Donor
24	REINFUSE	Char	1	\$X5841X.	\$1.	Stem Cell Reinfusion
25	rand_id	Char	10			Randomized subject ID
26	anc1days	Num	8			Days to Neutrophil Collection 1 Since Enrollment
27	anc2days	Num	8			Days to Neutrophil Collection 2 Since Enrollment
28	anc3days	Num	8			Days to Neutrophil Collection 3 Since Enrollment
29	mrwdays2	Num	8			Days to Marrow Collection Since Enrollment
30	bldchmdays	Num	8			Days to Blood Sample Chimerism Specimen Collection Since Enrollment
31	tcldays	Num	8			Days to T Cell Chimerism Specimen Collection Since Enrollment
32	infusedays	Num	8			Days to Infusion Since Enrollment

Data Set Name: inf.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	INFSITE	Char	2	\$XINFSITEX.	\$2.	Infection Site
2	INFTYP01	Char	1	\$X6372X.	\$1.	Infection Type 1
3	ORGN01	Char	3	\$X6373X.	\$3.	Organism 1
4	SVRTY01	Char	1	\$X6375X.	\$1.	Severity 1
5	INFTYP02	Char	1	\$X6376X.	\$1.	Infection Type 2
6	SVRTY02	Char	1	\$X6379X.	\$1.	Severity 2
7	INFTYP03	Char	1	\$X6380X.	\$1.	Infection Type 3
8	TRTINF	Char	1	\$X6384X.	\$1.	Infection treated
9	AGENT1	Char	50	\$X6385X.	\$50.	1st Agent Given
10	AGENT2	Char	50	\$X6386X.	\$50.	2nd Agent Given
11	AGENT3	Char	50	\$X6387X.	\$50.	3rd Agent Given
12	ADDAGENT	Char	1	\$X6388X.	\$1.	Additional Agents Given
13	rand_id	Char	10			Randomized subject ID
14	infstdays	Num	8			Days to Infection Onset Since Enrollment

Data Set Name: *inf_audited.sas7bdat*

Num	Variable	Type	Len	Format	Informat	Label
1	InfectionSite	Char	69	\$69.	\$69.	Infection Site
2	InfectionType	Char	13	\$13.	\$13.	Infection Type
3	InfectionSeverity	Char	26	\$26.	\$26.	Infection Severity
4	Organism	Char	83	\$83.	\$83.	Infection Organism
5	infectiondays	Num	8			Days to Infection Onset Since Enrollment
6	rand_id	Char	10			Randomized subject ID

Data Set Name: outcome.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	GENDER	Char	1	\$X638X.	1.	Recipient Gender
2	ETHNIC	Char	3	\$X639X.	3.	Ethnicity
3	raceA	Char	1	\$RACEF.		Race (recoded)
4	PROT	Char	5	5.	5.	BMT CTN Protocol #
5	TRTRUE	Char	100	100.	100.	Treatment Arm
6	stage	Char	100			Disease Stage
7	GVHDREG	Char	1	\$X569X.	1.	GVHD prophylaxis regimen
8	GVHDOTHR	Char	30	30.	30.	GVHD other regimen
9	CONDREGI	Char	1	\$X570X.	1.	Conditioning regimen
10	PPRIMDX	Char	1	\$X572X.	1.	Primary Disease at Enrollment
11	STRATA	Char	3	3.	3.	Risk Stratum: 001=good 002=poor
12	HLASCORE	Char	3	3.	3.	Calc Hla Match Score
13	SITESCR	Char	3	3.	3.	Site Hla score
14	CMVSTAT	Char	1	\$X4281X.	1.	CMV Status
15	ENGRFT1	Char	1	\$X5627X.	1.	Engraftment
16	ANC1SGF	Num	8	5.	5.	ANC Day 1
17	GFGIVEN	Char	1	\$X5428X.	1.	Growth Factor Given
18	RSPNDGF	Char	1	\$X5429X.	1.	Respond to Growth Factor
19	maxweek	Num	8			Week of Maximum aGVHD
20	maxgrade	Num	8			Maximum aGVHD Grade (Overall, by Day 98)
21	SEVCGVHD	Char	1	\$X490X.	1.	Chronic GVHD Maximum Overall Severity
22	GRDCGVHD	Char	1	\$X491X.	1.	Chronic GVHD Maximum Overall Grade
23	maxgrade100	Num	8			Max aGVHD grade post Day 100
24	czdthprm	Char	40	\$CAUSEF.	4.	Site-reported Cause of Death
25	Status_DRC	Char	23			Status of Date Review by DRC
26	COD_DRC	Char	30			Primary Cause of Death By DRC
27	aGVHDgradeby100_DRC	Num	8			Acute GVHD maximum Grade by Day 100 by DRC
28	aGVHDgradeafter100_DRC	Num	8			Acute GVHD maximum Grade After Day 100 by DRC
29	cGVHDgrade_DRC	Char	10			Chronic GVHD maximum Grade by DRC
30	ISPeriod	Char	13			Assess Period for Immunosuppressive Therapy at 2 years
31	IStherapy	Char	4			Immunosuppressive used at 2 years post transplant?
32	age	Num	8			Age at Enrollment(yrs)
33	death	Char	3			Death Reported?
34	ae	Char	3			Adverse Event Reported?
35	czdthsnd	Char	117			Site-reported Secondary COD (combined)
36	sectxp	Char	3			Non-protocol Specified Transplant?

Num	Variable	Type	Len	Format	Informat	Label
37	ose_srvtm	Num	8			Overall Survival Post Randomization (days)
38	ose_srvtm_mon	Num	8			Overall Survival Post Randomization (months)
39	ose_outcome	Char	9			Overall Survival Post Randomization Outcome
40	ose_srvcens	Num	8			Overall Survival Post Randomization Censor Indicator (1 means event)
41	ost_srvtm	Num	8			Overall Survival Post Transplant (days)
42	ost_srvtm_mon	Num	8			Overall Survival Post Transplant (months)
43	ost_outcome	Char	9			Overall Survival Post Transplant Outcome
44	ost_srvcens	Num	8			Overall Survival Post Transplant Censor Indicator (1 means event)
45	dfs_srvtm	Num	8			Disease-Free Survival Post Transplant (days)
46	dfs_srvtm_mon	Num	8			Disease-Free Survival Post Transplant (months)
47	dfs_outcome	Char	10			Disease-Free Survival Post Transplant Outcome
48	dfs_srvcens	Num	8			Disease-Free Survival Post Transplant Censor Indicator (1 means event)
49	ancday	Num	8			Neutrophil Recovery Post Transplant (days)
50	ancoutcome	Char	9			Neutrophil Recovery Post Transplant Outcome
51	anccens	Num	8			Neutrophil Recovery Post Transplant Censor Indicator (1 means event)
52	anc_CI	Num	8			Neutrophil Recovery Post Transplant Indicator for Cumulative Incidence (1 means event)
53	TRMday	Num	8			Treatment-related Mortality Post Transplant (days)
54	TRMmon	Num	8			Treatment-related Mortality Post Transplant (months)
55	TRMoutcome	Char	9			Treatment-related Mortality Post Transplant Outcome
56	TRMcens	Num	8			Treatment-related Mortality Post Transplant Censor Indicator (1 means event)
57	TRM_CI	Num	8			Treatment-related Mortality Post Transplant Indicator for Cumulative Incidence (1 means event)
58	relapseday	Num	8			Relapse Post Transplant (days)
59	relapsemon	Num	8			Relapse Post Transplant (months)
60	relapseoutcome	Char	9			Relapse Post Transplant Outcome
61	relapsecens	Num	8			Relapse Post Transplant Censor Indicator (1 means event)
62	relapse_CI	Num	8			Relapse Post Transplant Indicator for Cumulative Incidence (1 means event)
63	DAGE	Num	8	4.	4.	Donor age
64	DGENDER	Char	1	\$X2641X.	1.	Donor gender
65	DETHNIC	Char	1	\$X2647X.	1.	Donor ethnicity
66	DRACE	Char	2	\$X2648X.	2.	Donor race
67	DCMVST	Char	1	\$X3382X.	1.	Donor CMV status
68	reasonnotxp	Char	200			Reason for No Transplant and Status
69	maxaGVHDgradeoverall	Num	8			Maximum Acute GVHD overall across the study

Num	Variable	Type	Len	Format	Informat	Label
70	treatcross	Char	18			Treatment Crossover?
71	csf	Num	8			Planned Growth factor use (within 12 days) 0- No 1- Yes
72	hlamismatch	Num	8			Number of HLA Mismatch
73	karnofcat	Num	8			Karnofsky score
74	atggp	Num	8			ATG usage
75	p20day	Num	8			Days to platelet recovery to 20k or last contact or censoring
76	p20cens	Num	8			1=Platelet recovery to 20K, 0=no platelet recovery
77	p50day	Num	8			Days to platelet recovery to 50k or last contact or censoring
78	p50cens	Num	8			1=platelet recovery to 50K, 0=no platelet recovery
79	cd34p_kg	Num	8			CD34+ cell dose/kg
80	rand_donor_id	Char	9			Randomized donor ID
81	rand_id	Char	10			Randomized subject ID
82	cnsntdays0	Num	8			Days to Signing of Informed Consent Form Since Enrollment
83	condngdays	Num	8			Days to Initiation of Conditioning Regimen Since Enrollment
84	txdaystxp	Num	8			Days to Hematopoietic Stem Cell Infusion Since Enrollment
85	fudays	Num	8			Days to Last Follow-up Since Enrollment
86	lastctdays	Num	8			Days to Last Contact Since Enrollment
87	anc1days	Num	8			Days to Neutrophil Collection 1 Since Enrollment
88	anc1sgdays	Num	8			Days to Neutrophil Collection 1 Since Enrollment
89	relapsdays	Num	8			Days to Relapse or Progression Since Enrollment
90	daystransp	Num	8			Days to Non-protocol Transplant Since Enrollment
91	gvhdondays	Num	8			Days to aGVHD Onset Since Enrollment
92	maxdays	Num	8			Days to Maximum aGVHD (By 98 Days Post Transplant) Since Enrollment
93	stagedays234	Num	8			Days to Grades 2-4 aGVHD Since Enrollment
94	stagedays34	Num	8			Days to Grades 3-4 aGVHD Since Enrollment
95	daysdngcgv	Num	8			Days to First Diagnosis of cGVHD Since Enrollment
96	agvp100days	Num	8			Days to aGVHD (By 100 Days Post Transplant) Since Enrollment
97	dthdays	Num	8			Days to Death Since Enrollment
98	dthdays_drc	Num	8			Days to Confirmed Death Since Enrollment
99	relapsedays_drc	Num	8			Days to Confirmed Relapse Since Enrollment
100	agvhddaysby100_drc	Num	8			Days to Confirmed aGVHD Onset (By 100 Days Post Transplant) Since Enrollment
101	agvhddaysafter100_drc	Num	8			Days to Confirmed aGVHD Onset (After 100 Days Post Transplant) Since Enrollment
102	cgvhddays_drc	Num	8			Days to First Confirmed cGVHD Onset Since Enrollment
103	daysdx	Num	8			Days to Disease Diagnosis Since Enrollment
104	enrldays	Num	8			Days to Enrollment Since Enrollment

Data Set Name: rlp.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	RELAPSDX	Char	1	\$XDX0201X.	\$1.	Disease
2	RLALLBPB	Char	1	\$X1596X.	\$1.	Leukemic blasts in PB
3	RLALLDYS	Char	1	\$X1597X.	\$1.	Dysplastic changes in BM
4	RLALLBL1	Char	1	\$X1598X.	\$1.	Leukemic blasts 1
5	RLALLPR1	Num	8	4.	4.	Leukemic blast percent 1
6	RLALLBAT	Char	1	\$X1599X.	\$1.	Blasts attribute to other
7	RLALLBA0	Char	50	\$50.	\$50.	Blst attrib other specify
8	RLALLBL2	Char	10	\$X1600X.	\$10.	Leukemic blasts 2
9	RLALLPR2	Num	8	4.	4.	Leukemic blasts percent 2
10	RLALEXTR	Char	1	\$X1601X.	\$1.	Detected at extramed site
11	RLALCSF	Char	1	\$X1602X.	\$1.	Detected in CSF
12	RLCMIMMC	Char	1	\$X1603X.	\$1.	Immature hemato cells
13	RLCMMYHY	Char	1	\$X1604X.	\$1.	Myeloid hyperplasia
14	RLCMCYT1	Char	1	\$X1615X.	\$1.	Translocation exhibited 1
15	RLCMNAN1	Num	8	4.	4.	Metaphases analyzed 1
16	RLCMNTR1	Num	8	4.	4.	Number exhibit trnslectn 1
17	RLCMCYT2	Char	1	\$X1616X.	\$1.	Translocation exhibited 2
18	RLCMNAN2	Num	8	4.	4.	Metaphases analyzed 2
19	RLCMNTR2	Num	8	4.	4.	Number exhibit trnslectn 2
20	RLMDMRA	Char	1	\$X1617X.	\$1.	Reappear morph abnorm
21	RLMD2MRA	Char	1	\$X1618X.	\$1.	Reappear morph abnorm 2nd
22	RLMDCY1	Char	1	\$X1619X.	\$1.	Reappear pretx abnorm 1
23	RLMDCYA1	Num	8	4.	4.	Num metaphase analyze 1
24	RLMDCYN1	Num	8	4.	4.	Num metaphase abnorm 1
25	RLMDCY2	Char	1	\$X1620X.	\$1.	Reappear pretx abnorm 2
26	RLMDCYA2	Num	8	4.	4.	Num metaphase analyze 2
27	RLMDCYN2	Num	8	4.	4.	Num metaphase abnorm 2
28	RLRLPREV	Char	1	\$X1621X.	\$1.	Relapse reversal treatmnt
29	rand_id	Char	10			Randomized subject ID
30	rlpbpdays	Num	8			Days to Appearance of Leukemia Blast Cells Since Enrollment
31	rldysdays	Num	8			Days to Appearance of Dyplastic Changes in Blood Marrow Since Enrollment
32	rlalldays1	Num	8			Days to Documentation of Leukemia Blasts Since Enrollment
33	rlalldays2	Num	8			Days to Documentation of Second Biopsy Leukemia Blasts Since Enrollment
34	rlalexdays	Num	8			Days to Detection of Leukemia at an Extramedullary Site Since Enrollment

Num	Variable	Type	Len	Format	Informat	Label
35	rlalcsdays	Num	8			Days to Detection of Leukemic Cells in the Cerebrospinal Fluid Since Enrollment
36	rlcmimdays	Num	8			Days to Documentation of Immature Hematopoietic Cells in the Peripheral Blood Since Enrollment
37	rlcmmydays	Num	8			Days to Documentation of Myeloid Hyperplasia in the Bone Marrow Since Enrollment
38	rlmcydays1	Num	8			Days to Detection of Metaphases Exhibiting 9;22 Translocation Since Enrollment
39	rlmcydays2	Num	8			Days to Detection of Metaphases Exhibiting 9;22 Translocation in a Second Analysis Since Enrollment
40	rlmdmadays1	Num	8			Days to Appearance of Morphologic Abnormalities in Bone Marrow Since Enrollment
41	rlmdmadays2	Num	8			Days to Appearance of Morphologic Abnormalities in a Second Bone Marrow Specimen Since Enrollment
42	rlmncydays1	Num	8			Days to Cytogenetic Analysis Since Enrollment
43	rlmncydays2	Num	8			Days to Second Sytogenetic Analysis Since Enrollment
44	rlrevdays	Num	8			Days to Start of Therapy for Relapse Reversal Since Enrollment

Data Set Name: *sgf.sas7bdat*

Num	Variable	Type	Len	Format	Informat	Label
1	DECANC	Char	1	\$X9045X.	\$1.	Decline in ANC
2	ANC1SGF	Num	8	4.	4.	ANC Day 1
3	ANC2SGF	Num	8	4.	4.	ANC Day 2
4	ANC3SGF	Num	8	4.	4.	ANC Day 3
5	GFGIVEN	Char	1	\$X9046X.	\$1.	Growth Factor Given
6	RSPNDGF	Char	1	\$X9047X.	\$1.	Respond to Growth Factor
7	rand_id	Char	10			Randomized subject ID
8	anc1sgdays	Num	8			Days to Neutrophil Collection 1 Since Enrollment
9	anc2sgdays	Num	8			Days to Neutrophil Collection 2 Since Enrollment
10	anc3sgdays	Num	8			Days to Neutrophil Collection 3 Since Enrollment

Data Set Name: tx2.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	VISNO	Char	4	\$4.	\$4.	VISNO
2	HYPOTENS	Char	1	\$X1983X.	\$1.	Hypotension
3	LVENTSYS	Char	1	\$X1984X.	\$1.	Left Ventricular Systolic
4	CRDARYTH	Char	1	\$X1985X.	\$1.	Cardiac Arrhythmia
5	DIC	Char	1	\$X1986X.	\$1.	DIC
6	MUCOEXAM	Char	1	\$X1987X.	\$1.	Mucositis Clinical Exam
7	MUCOFUNC	Char	1	\$X1988X.	\$1.	Mucositis Functional
8	HEMORRAG	Char	1	\$X1989X.	\$1.	Hemorrhage
9	RNLFAIL	Char	1	\$X1990X.	\$1.	Renal Failure Severe Dial
10	DIALYSIS	Char	1	\$X1991X.	\$1.	Received Dialysis
11	CYSTITIS	Char	1	\$X1992X.	\$1.	Cystitis
12	SOMNOLNC	Char	1	\$X1993X.	\$1.	Somnolence
13	SEIZURE	Char	1	\$X1994X.	\$1.	Seizures
14	SEIZRGRD	Char	1	\$X1995X.	\$1.	Seizure Grade
15	VASCLEAK	Char	1	\$X1996X.	\$1.	Vascular Leak
16	OSTEONEC	Char	10	\$X1997X.	\$10.	Osteonecrosis
17	VAGINITIS	Char	1	\$X1998X.	\$1.	Vaginitis
18	HYPXIA	Char	1	\$X1999X.	\$1.	Hypoxia
19	DYSPNEA	Char	1	\$X2000X.	\$1.	Dyspnea
20	PULFIBRO	Char	10	\$X2001X.	\$10.	Pulmonary Fibrosis
21	FEVDONE	Char	1	\$X2002X.	\$1.	Was FEV Done?
22	FEVVALUE	Num	8	4.	4.	Reported FEV Value
23	FVCDONE	Char	1	\$X2003X.	\$1.	Was FVC Done?
24	FVCVALUE	Num	8	4.	4.	Reported FVC Value
25	ABLVRFNC	Char	1	\$X2004X.	\$1.	Abnormal Liver Function
26	JAUNDICE	Char	1	\$X2005X.	\$1.	Jaundice
27	HEPATOMG	Char	1	\$X2006X.	\$1.	Hepatomegaly
28	QUADPAIN	Char	1	\$X2007X.	\$1.	Right Upper Quadrant Pain
29	WIEGHTGN	Char	1	\$X2008X.	\$1.	Weight Gain (>5)
30	OTHERABN	Char	1	\$X2009X.	\$1.	Other Liver Abnormalities
31	OTHSPEC1	Char	50	\$50.	\$50.	Specify Other Symptoms
32	TX2VODET	Char	1	\$X2332X.	\$1.	VOD Etiology
33	TX2VODBI	Char	1	\$X2333X.	\$1.	VOD Biopsy
34	TX2VODDP	Char	1	\$X2334X.	\$1.	VOD Doppler
35	TX2GVHET	Char	1	\$X2335X.	\$1.	GHVD Etiology
36	TX2GVHBI	Char	1	\$X2336X.	\$1.	GVHD Biopsy

Num	Variable	Type	Len	Format	Informat	Label
37	TX2GVHDP	Char	1	\$X2337X.	\$1.	GVHD Doppler
38	TX2INFET	Char	1	\$X2338X.	\$1.	Infection Etiology
39	TX2INFBI	Char	1	\$X2339X.	\$1.	Infection Biopsy
40	TX2INFDP	Char	1	\$X2340X.	\$1.	Infection Doppler
41	TX2OTHET	Char	1	\$X2341X.	\$1.	Other Etiology
42	TX2UKNET	Char	1	\$X2342X.	\$1.	Unknown Etiology
43	OTHSPEC2	Char	50	\$50.	\$50.	Specify Other Etiology
44	RCVMTX	Char	1	\$X2010X.	\$1.	Receive Methotrexate
45	MTHFULL1	Char	1	\$X2343X.	\$1.	Methotrexate Full Dose 1
46	MTHFULL2	Char	1	\$X2344X.	\$1.	Methotrexate Full Dose 2
47	MTHFULL3	Char	1	\$X2345X.	\$1.	Methotrexate Full Dose 3
48	MTHFULL4	Char	1	\$X2346X.	\$1.	Methotrexate Full Dose 4
49	MTHDOSE1	Num	8	6.1	6.1	Methotrexate Dose 1
50	MTHDOSE2	Num	8	6.1	6.1	Methotrexate Dose 2
51	MTHDOSE3	Num	8	6.1	6.1	Methotrexate Dose 3
52	MTHDOSE4	Num	8	6.1	6.1	Methotrexate Dose 4
53	WHLDRD1	Char	1	\$X2347X.	\$1.	Withheld Renal Dysfxn 1
54	WHLDRD2	Char	1	\$X2348X.	\$1.	Withheld Renal Dysfxn 2
55	WHLDRD3	Char	1	\$X2349X.	\$1.	Withheld Renal Dysfxn 3
56	WHLDRD4	Char	1	\$X2350X.	\$1.	Withheld Renal Dysfxn 4
57	WHLDMTX1	Char	1	\$X2351X.	\$1.	Withheld Mucosal Tox 1
58	WHLDMTX2	Char	1	\$X2352X.	\$1.	Withheld Mucosal Tox 2
59	WHLDMTX3	Char	1	\$X2353X.	\$1.	Withheld Mucosal Tox 3
60	WHLDMTX4	Char	1	\$X2354X.	\$1.	Withheld Mucosal Tox 4
61	WHLDFLA1	Char	1	\$X2355X.	\$1.	Withheld Fluid Accum 1
62	WHLDFLA2	Char	1	\$X2356X.	\$1.	Withheld Fluid Accum 2
63	WHLDFLA3	Char	1	\$X2357X.	\$1.	Withheld Fluid Accum 3
64	WHLDFLA4	Char	1	\$X2358X.	\$1.	Withheld Fluid Accum 4
65	WHLDLVR1	Char	1	\$X2359X.	\$1.	Withheld Liver Dysfxn 1
66	WHLDLVR2	Char	1	\$X2360X.	\$1.	Withheld Liver Dysfxn 2
67	WHLDLVR3	Char	1	\$X2361X.	\$1.	Withheld Liver Dysfxn 3
68	WHLDLVR4	Char	1	\$X2362X.	\$1.	Withheld Liver Dysfxn 4
69	WHLDOTH1	Char	1	\$X2363X.	\$1.	Withheld Other Reason 1
70	WHLDOTH2	Char	1	\$X2364X.	\$1.	Withheld Other Reason 2
71	WHLDOTH3	Char	1	\$X2365X.	\$1.	Withheld Other Reason 3
72	WHLDOTH4	Char	1	\$X2366X.	\$1.	Withheld Other Reason 4
73	MTHOTHR1	Char	25	\$25.	\$25.	Meth Specify Other 1
74	MTHOTHR2	Char	25	\$25.	\$25.	Meth Specify Other 2
75	MTHOTHR3	Char	25	\$25.	\$25.	Meth Specify Other 3

Num	Variable	Type	Len	Format	Informat	Label
76	MTHOTHR4	Char	25	\$25.	\$25.	Meth Specify Other 4
77	rand_id	Char	10			Randomized subject ID
78	txevaldays	Num	8			Days to Toxicity Evaluation Since Enrollment
79	mthdays1	Num	8			Days to Methotrexate Reception 1 Since Enrollment
80	mthdays2	Num	8			Days to Methotrexate Reception 2 Since Enrollment
81	mthdays3	Num	8			Days to Methotrexate Reception 3 Since Enrollment
82	mthdays4	Num	8			Days to Methotrexate Reception 4 Since Enrollment

Data Set Name: txp.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	CMVSTAT	Char	1	\$X13216X.	\$1.	CMV Status
2	rand_id	Char	10			Randomized subject ID
3	txdaystxp	Num	8			Days to Hematopoietic Stem Cell Infusion Since Enrollment
4	condngdays	Num	8			Days to Initiation of Conditioning Regimen Since Enrollment

Data Set Name: vax.sas7bdat

Num	Variable	Type	Len	Format	Informat	Label
1	VISNO	Char	4	\$4.	\$4.	VISNO
2	DTTIME	Char	5	\$5.	\$5.	dT Vaccine Time
3	HEPBTIME	Char	5	\$5.	\$5.	Hep B Vaccine Time
4	PCV7TIME	Char	5	\$5.	\$5.	PCV7 Vaccine Time
5	PPV23TIM	Char	5	\$5.	\$5.	PPV23 Vaccine Time
6	rand_id	Char	10			Randomized subject ID
7	dtadays	Num	8			Days to Tetanus dT Vaccination Since Enrollment
8	hepbdays	Num	8			Days to Hepatitis B Vaccination Since Enrollment
9	pcv7days	Num	8			Days to PCV7 Vaccination Since Enrollment
10	ppv23days	Num	8			Days to PPV23 Vaccination Since Enrollment